Head of the class

It's increasingly clear that buysiders expect nothing but stellar numbers for HCV drug Sovaldi sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD). The stock barely moved last week despite the biotech posting 2Q14 Sovaldi sales that blew away the Street's estimates.

Late Wednesday, Gilead reported 2Q14 results that beat the Street, including $3.5 billion in Sovaldi sales. The figure was far above the sellside's $2.5-$2.6 billion estimate but was in line with the buyside consensus, according to LSP-Life Science Partners' Joep Muijrers...